Christopher Hoimes, DO

Publications

Rosenberg, Jonathan E., Thomas W. Flaig, Terence W. Friedlander, Matthew I. Milowsky, Sandy Srinivas, Daniel Peter Petrylak, Jaime R. Merchan, et al. “Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Mar, Nataliya, Terence W. Friedlander, Christopher J. Hoimes, Thomas W. Flaig, Mehmet Asim Bilen, Arjun Vasant Balar, Elizabeth Henry, et al. “Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Hoimes, Christopher J., Julie N. Graff, Scott T. Tagawa, Clara Hwang, Deepak Kilari, A. J. Ten Tije, Aurelius Omlin, et al. “KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Kaimakliotis, Hristos Z., Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L. Smith, et al. “Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Khaki, Ali Raza, Ang Li, Leonidas N. Diamantopoulos, Mehmet A. Bilen, Victor Santos, John Esther, Rafael Morales-Barrera, et al. “Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.” Cancer 126, no. 6 (March 15, 2020): 1208–16. https://doi.org/10.1002/cncr.32645.

PMID
31829450
Full Text

Flaig, Thomas W., Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, et al. “Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 18, no. 3 (March 2020): 329–54. https://doi.org/10.6004/jnccn.2020.0011.

PMID
32135513
Full Text

Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaishampayan, et al. “Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.” J Clin Oncol 38, no. 5 (February 10, 2020): 395–405. https://doi.org/10.1200/JCO.19.01638.

PMID
31774688
Full Text

Atukorale, Prabhani U., Shruti P. Raghunathan, Vanitha Raguveer, Taylor J. Moon, Carolyn Zheng, Peter A. Bielecki, Michelle L. Wiese, et al. “Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity.” Cancer Res 79, no. 20 (October 15, 2019): 5394–5406. https://doi.org/10.1158/0008-5472.CAN-19-0381.

PMID
31431457
Full Text

Sadeghi, Sarmad, Susan G. Groshen, Denice D. Tsao-Wei, Rahul Parikh, Amir Mortazavi, Tanya B. Dorff, Cheryl Kefauver, et al. “Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).” J Clin Oncol 37, no. 29 (October 10, 2019): 2682–88. https://doi.org/10.1200/JCO.19.00861.

PMID
31390274
Full Text

Pages